GCM
MRSN

Graham Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Graham Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,989
Closed -$71.1K – 1434
2024
Q4 		$71.1K Buy
1,989
+292
+17% +$15.1K ﹤0.01% 1175
2024
Q3 		$80.2K Sell
1,697
-342
-17% -$15.1K ﹤0.01% 1022
2024
Q2 		$102K Buy
+2,039
New +$147K ﹤0.01% 944
2024
Q1 		– Sell
-472
Closed -$27.4K – 1219
2023
Q4 		$27.4K Sell
472
-1,401
-75% -$56.4K ﹤0.01% 952
2023
Q3 		$59.5K Sell
1,873
-1,077
-37% -$51.2K ﹤0.01% 961
2023
Q2 		$243K Buy
+2,950
New +$432K 0.01% 761
2022
Q3 		– Sell
-8,123
Closed -$938K – 1216
2022
Q2 		$938K Buy
+8,123
New +$764K 0.04% 460

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Graham Capital Management's MRSN Position: Q1 2025 in Review

Graham Capital Management sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 1,989 shares — an estimated $71.1K sold.

Graham Capital Management first reported a position in MRSN in Q2 2022 and held it in 7 quarters. The position peaked at $938K in Q2 2022. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Graham Capital Management reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 1,989 Mersana Therapeutics shares in Q1 2025, an estimated $71.1K.
  • Graham Capital Management first reported a position in Mersana Therapeutics in Q2 2022 and held it in 7 quarters.
  • Graham Capital Management's Mersana Therapeutics position peaked at $938K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.